Repository logo
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
  • Communities & Collections
  • All of DSpace
  • English
  • Català
  • Čeština
  • Deutsch
  • Español
  • Français
  • Gàidhlig
  • Italiano
  • Latviešu
  • Magyar
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Suomi
  • Svenska
  • Türkçe
  • Tiếng Việt
  • Қазақ
  • বাংলা
  • हिंदी
  • Ελληνικά
  • Yкраї́нська
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "MUHAMMAD SHOAIB KHAN"

Now showing 1 - 1 of 1
Results Per Page
Sort Options
  • Loading...
    Thumbnail Image
    Item
    Synthesis of anti-interferon beta 1a antibody in MICE and its characterization
    (UMT Lahore, 2023-09-15) MUHAMMAD SHOAIB KHAN; RIZWAN ULLAH
    Multiple Sclerosis (MS) is a disease of nervous system. In this autoimmune disease, the immune system of the body starts attacking the healthy nerves and degenerates the myelin sheath present on them. This results in the formation of scars on the multiple sites on nerves. In the patients of MS, brain to body communication is affected and other symptoms like decline in mobility, blurriness and double vision, Lhermitte sign, and lack of sensation is noticed. Different therapies for multiples sclerosis are used but most commonly used therapy is disease modifying therapy using beta interferons. Considerable clinical problem is the formation of anti-IFN neutralizing antibodies (NABs) against the drug which decrease the therapeutic effectiveness. To confirm this, we immunized the mice with BSA and OAS conjugated activated interferon beta 1a for five weeks, then we took the blood from the mice through cardiac puncture and isolated the serum by centrifugation. We performed ELISA and Immuno Dot Blot tests both of which showed positive test results which confirmed the formation of anti-IFN neutralizing antibody. In future we can further characterize these NABs to exactly know about the mechanism of antibody production against the injected drug, to launch an appropriate treatment mechanism where clinical efficacy of the treatment would sustain.

DSpace software copyright © 2002-2026 LYRASIS

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback